ATE155690T1 - Rekombinanter lebender impfstoff gegen gram- negative enterische pathogene - Google Patents

Rekombinanter lebender impfstoff gegen gram- negative enterische pathogene

Info

Publication number
ATE155690T1
ATE155690T1 AT92106281T AT92106281T ATE155690T1 AT E155690 T1 ATE155690 T1 AT E155690T1 AT 92106281 T AT92106281 T AT 92106281T AT 92106281 T AT92106281 T AT 92106281T AT E155690 T1 ATE155690 T1 AT E155690T1
Authority
AT
Austria
Prior art keywords
strains
enteric pathogens
negative enteric
vaccine against
against gram
Prior art date
Application number
AT92106281T
Other languages
English (en)
Inventor
Jean-Francois Viret
Stanly J Cryz Jr
Didier Favre
Original Assignee
Schweiz Serum & Impfinst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schweiz Serum & Impfinst filed Critical Schweiz Serum & Impfinst
Application granted granted Critical
Publication of ATE155690T1 publication Critical patent/ATE155690T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92106281T 1992-04-10 1992-04-10 Rekombinanter lebender impfstoff gegen gram- negative enterische pathogene ATE155690T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG1996001047A SG46987A1 (en) 1992-04-10 1992-04-10 Recombinant live vaccines
EP92106281A EP0564689B1 (de) 1992-04-10 1992-04-10 Rekombinanter lebender Impfstoff gegen Gram-negative enterische Pathogene

Publications (1)

Publication Number Publication Date
ATE155690T1 true ATE155690T1 (de) 1997-08-15

Family

ID=26130874

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92106281T ATE155690T1 (de) 1992-04-10 1992-04-10 Rekombinanter lebender impfstoff gegen gram- negative enterische pathogene

Country Status (7)

Country Link
EP (1) EP0564689B1 (de)
AT (1) ATE155690T1 (de)
DE (2) DE69221120T2 (de)
DK (1) DK0564689T3 (de)
ES (1) ES2083343T3 (de)
GR (1) GR3024848T3 (de)
SG (1) SG46987A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08506963A (ja) * 1993-02-22 1996-07-30 ザ ジェネラル ホスピタル コーポレーション 生ワクチン菌株における異種抗原
BR9609882A (pt) * 1995-08-04 1999-07-27 Univ Guelph Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana
US20020028215A1 (en) 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
GR950300072T1 (en) * 1995-10-13 1996-01-31 Schweiz Serum & Impfinst Recombinant live vaccines against Gram-negative enteric pathogens
US6036953A (en) * 1996-11-29 2000-03-14 The General Hospital Corporation Heterologous antigens in live cell V. cholerae strains
US6399074B1 (en) 1998-07-24 2002-06-04 Megan Health, Inc. Live attenuated salmonella vaccines to control avian pathogens
EP1227839A2 (de) * 1999-11-10 2002-08-07 National Research Council Of Canada Lebende bakterielle impfstoffe gegen escherichia coli 0157:h7
EP1543836A1 (de) * 2003-12-17 2005-06-22 Berna Biotech AG Rekombinante Stamm von Vibrio cholerae und Impfstoff, der diesem Stamm enthält

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3856935A (en) * 1971-04-29 1974-12-24 Schweiz Serum & Impfinst Oral typhoid vaccine and method of preparing the same
US4632830A (en) * 1981-07-31 1986-12-30 The United States Of America As Represented By The Secretary Of The Army Oral vaccine for immunization against enteric disease
GB8314645D0 (en) * 1983-05-26 1983-06-29 Wellcome Found Bivalent vaccines
EP0250614A1 (de) * 1986-06-23 1988-01-07 Serum Und Impfinstitut Und Institut Zur Erforschung Der Infektionskrankheiten Schweiz. Chromosomale Nukleotid-DNS-Fragmente, die für Zuckersynthetasen und Glukosyltransferasen kodieren
EP0377711A1 (de) * 1988-06-20 1990-07-18 Luminis Pty. Limited Dns-sonden für serotypierung
AR242989A1 (es) * 1988-07-15 1993-06-30 Inst Pasteur I Nat De La Sante Metodo para modificar una cepa salvaje de una shigella entero-invasora para producir una cepa modificada apta para preparar una vacuna contra la cepa salvaje y cepa de shigella asi modificada.
WO1991018092A1 (en) * 1990-05-23 1991-11-28 University Of Maryland At Baltimore Acid-tolerant salmonella typhi, double aro mutants thereof and use as an oral vaccine for typhoid fever

Also Published As

Publication number Publication date
GR3024848T3 (en) 1998-01-30
ES2083343T3 (es) 1997-12-01
EP0564689A1 (de) 1993-10-13
EP0564689B1 (de) 1997-07-23
SG46987A1 (en) 1998-03-20
ES2083343T1 (es) 1996-04-16
DE69221120T2 (de) 1998-02-26
DE69221120D1 (de) 1997-08-28
DK0564689T3 (da) 1998-02-16
DE564689T1 (de) 1996-06-27

Similar Documents

Publication Publication Date Title
Bradbury et al. Investigation of a Campylobacter jejuni outbreak by serotyping and chromosomal restriction endonuclease analysis
ATE196773T1 (de) Infektiösen bronchitis virus 4/91 enthaltender geflügel-impfstoff
DE69221120D1 (de) Rekombinanter lebender Impfstoff gegen Gram-negative enterische Pathogene
PL318095A1 (en) Streptococcus equi vaccine
DE69941567D1 (de) Antigene aus neisseria meningitidis
ATE167061T1 (de) Kreuzschützende salmonella impfstoffe
HUP9900919A2 (hu) 2,5-D-Mannóz-csoportot tartalmazó B antigén csoportba tartozó II és III típusú streptococcus poliszacharid-fragmentumok és ezeket tartalmazó vakcinakonjugátumok
Confer et al. Serum antibody responses of cattle to iron-regulated outer membrane proteins of Pasteurella haemolytica A1
DE69419966D1 (de) Impstoff gegen Streptococcus suis-Infektion
DE60325696D1 (de) Synthese von lipopolysaccharid-protein konjugatvaccinen über die lipid-a region nach entfernung des glycosidischen phosphatresidüs
NO176004C (no) Fremgangsmåte ved fremstilling av vaksine mot hunde-coronavirus
HUP0302612A2 (hu) Salmonella vakcina
Ogunnariwo et al. Evidence for non-siderophore-mediated acquisition of transferrin-bound iron by Pasteurella multocida
ATE392429T1 (de) Lebend-impfstoff gegen heliobacter pylori
DE69632141D1 (de) Lebend-impfstoffe gegen gram-negative pathogene, die heterologe o-antigene exprimieren
DE69316026D1 (de) Als fischimpfstoff anwendbare attenuierte aeromonas salmonicida-stämme
FI971402A0 (fi) Menetelmä voimistettujen antigeenisten Helico-bacter-lajien ja niitä sisältävien rokotteiden valmistamiseksi
Sippel et al. Homogeneity of protein serotype antigens in Neisseria meningitidis group A
DE60042489D1 (de) Impfstoff gegen neisseria infektion
Davies et al. Comparison of outer-membrane proteins of Pasteurella haemolytica expressed in vitro and in vivo in cattle
Albert et al. Serotype distribution of Campylobacter jejuni and Campylobacter coli isolated from hospitalized patients with diarrhea in central Australia
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
Sibalin Cross-neutralization tests with swine enterovirus strain S 180/4, and Teschen, Talfan, and swine polio-encephalomyelitis viruses
DK0587800T3 (da) Immunomodulatoriske azaspiraner
ATE16348T1 (de) Ozon-inaktivierte keime als vakzine.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee